J
Jiwei Liu
Researcher at Dalian Medical University
Publications - 34
Citations - 5103
Jiwei Liu is an academic researcher from Dalian Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 8 publications receiving 4328 citations.
Papers
More filters
Journal ArticleDOI
Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma
Feng Lian Qu,Xue Zhi Hao,Shu kui Qin,Jiwei Liu,Guang jie Sui,Qiang Chen,Too Qu,He Ping Zhang,Yan Sun +8 more
TL;DR: As2O3 is effective in the management of primary hepatocarcinoma, with a significant analgesic effect, and to some extent, it can extend TTP and MST in advanced liver cancer patients, while the treatment is well tolerated in the majority of patients.
Journal ArticleDOI
Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Chen,Hui-fang Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Meilin Liu,Yong Jiang,Chuan Gu +21 more
TL;DR: In this article , the authors reported the CNS efficacy of furmonertinib compared with gefitinib in untreated EGFR-sensitizing mutation-positive NSCLC from the FURLONG study.
Journal Article
Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors
Pin Zhang,Feng-yi Feng,L Y Wu,Yi Hu,Jiwei Liu,Ya-jie Gao,Xiao-qian Guan,Kejun Nan,Aili Suo,Xiuwen Wang,Mao-hong Zhang,Wen-dong Zhang,Chao-wu Li,Yang Zhang,Jin-bo Zhao +14 more
TL;DR: Compared with the control group treated by DDP-based regimen, nedaplatin-based combination chemotherapy has similar effect on HNSCC, NSCLC, ovary carcinoma and esophageal cancer.
Journal Article
Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma
Mei Dong,Feng-yi Feng,Yang Zhang,Guang-ru Xie,Ya-Jie Wang,Jiwei Liu,Santai Song,Qinghua Zhou,Jun Ren,Shun-Chang Jiao,Jin Li,Xiuwen Wang,Qiang Chen,Zhehai Wang,Nong Xu,Jifeng Feng +15 more
TL;DR: Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety.
Peer Review
Ef fi cacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
Yuankai Shi,Shiman Wu,Kenneth K. Wang,Shundong Cang,Wen-xiu Yao,Yun Fan,Lin Wu,Meijuan Huang,Xing-Ya Li,Yueyin Pan,Zhixiong Yang,Bo Zhu,Gongyan Chen,Jian Hua Shi,Meili Sun,Jian Fang,Lianjun Wang,Zhaohong Chen,Chunling Liu,Jingzhang Li,Jiwei Liu,Shenghua Sun,Yanqiu Zhao,Yanzhen Guo,Zili Meng,Zhefeng Liu,Zhigang Han,Aa,Rui Ma,Sheng-Juan Hu,Guofang Zhao,Zheng Liu,ee,Congying Xie,Ff,Diansheng Zhong,Huimin Zhao,Hui-Qing Yu,Longzhen Zhang,jj,Minghong Bi,Shanyong Yi,Shu-Yan Guo,Tienan Yi,Wen Li,oo,Ying Li,Yongqian Shu,Zhendong Chen,Zhongliang Guo,Michael Greco,tt,Ting Wang,Hai-li Shen +53 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of rezivertinib in patients with locally advanced or metastatic/ recurrent EGFR T790M-mutated NSCLC.